The sarm-demic: Social media algorithms, e-commerce loopholes, and the normalization of experimental pharmacology in recreational users

The epidemiology of performance- and image-enhancing drug (PIED) use has shifted toward non-athlete recreational users who primarily seek cosmetic physical changes. This review evaluates the unregulated distribution of Selective Androgen Receptor Modulators (SARMs). We analyze this trend at the intersection of experimental pharmacology, social media algorithms, and e-commerce loopholes. We comprehensively synthesized the literature to contrast the clinical intent of investigational SARMs with the toxicological reality of digital markets. Phase II trials demonstrated that tissue-selective compounds like enobosarm increase lean body mass at controlled micro-doses ranging from 0.1 to 3 mg daily. However, the online market promotes supraphysiological dosing regimens exceeding 20 mg daily. Chemical analyses reveal widespread mislabeling and cross-contamination with unapproved experimental compounds, including PPAR-δ agonists and growth hormone secretagogues. Recreational dosing bypasses tissue selectivity. Case reports document severe lipid dysregulation, hypogonadotropic hypogonadism requiring unmonitored post-cycle therapy, and idiosyncratic drug-induced liver injury (DILI). Histologically, these hepatic injuries predominantly show bland centrilobular canalicular cholestasis, though instances of significant hepatocellular injury have also been documented. SARM misuse is exacerbated by social media, where young adults enter algorithmic echo chambers that amplify muscle dysmorphia and minimize pharmacological risks. Addressing SARM misuse requires an update to traditional anti-doping frameworks, with public health strategies focusing on e-commerce regulation, algorithmic transparency, and targeted diagnostic training for clinicians.